EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Efficacy and safety of interferon alpha-2b aerosol therapy for patients infected with the SARS-CoV-2 omicron variant: A randomized controlled single-blind study

Yinpeng Jin, Xianming Meng, Zhiping Qian, Jun Zhao, Ying Lv, Yun Ling, Xiaohong Fan

Cellular Immunology · 2025

DOI: 10.1016/j.cellimm.2025.104992 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cellular Immunology, 2025. Verfasst von Yinpeng Jin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19, COVID-19 Drug Treatment, Interferon alpha-2. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Shanghai Key Discipline Construction Project, Shanghai Medical College, Fudan University, Shanghai Municipal Hospital Development Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy of Type I interferon (IFN) in treating COVID-19 has remained controversial. In this study, we conducted a randomized, single-blind clinical trial to evaluate the efficacy of recombinant human interferon alpha 2b (IFN-alpha2b) in treating COVID-19 patients during the Omicron outbreak in Shanghai in 2022. The study cohort included 505 patients, classified as asymptomatic, mild, or moderate based on clinical symptoms. The cohort was divided into an experimental group, which received a 7-day course of nebulized inhalation of IFN-alpha2b, and a control group, which received an identical treatment course using physiological saline in place of IFN-alpha2b. Effectiveness and safety were assessed by measuring the length of hospital stay, improvement in clinical symptoms, and occurrence of adverse events. While there were no significant differences in overall hospital stay or symptom improvement between the two groups, IFN-alpha2b treatment was associated with a significantly shorter hospitalization time in the asymptomatic subgroup. Multivariate Cox regression analysis identified IFN nebulization therapy as a positive predictor of discharge within 12 days, alongside the white blood cell count at admission, and the IL-4 level at admission as a potential negative predictor. Regarding safety, there was no significant difference in the incidence of adverse reactions between the two groups during treatment. Collectively, our study suggests that Type I IFN, when administered via nebulized inhalation, may offer benefits specifically for the asymptomatic subgroup among COVID-19 patients, indicating selective efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19COVID-19 Drug TreatmentInterferon alpha-2SARS-CoV-2AdultAgedFemaleHumansMaleMiddle AgedAdministration, InhalationAerosolsChinaLength of StaySingle-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

Aerosol inhalationCOVID-19Immune biomarkersInterferon alpha-2bOmicron variant

Substanzen

AerosolsAntiviral AgentsInterferon alpha-2

Autor:innen und Institutionen

  • Center of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Department of Clinical Research, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Department of Liver Intensive Care Uint, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Department of Pediatrics, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Department of Integrative Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Electronic address: yun.ling@shphc.org.cn.

Förderung

  • Shanghai Key Discipline Construction Project
  • Shanghai Medical College, Fudan University
  • Shanghai Municipal Hospital Development Center

Zitieren

APA

Jin, Y., Meng, X., Qian, Z., Zhao, J., Lv, Y., Ling, Y., & Fan, X. (2025). Efficacy and safety of interferon alpha-2b aerosol therapy for patients infected with the SARS-CoV-2 omicron variant: A randomized controlled single-blind study. Cellular Immunology. https://doi.org/10.1016/j.cellimm.2025.104992

Vancouver

Jin Y, Meng X, Qian Z, Zhao J, Lv Y, Ling Y, et al. Efficacy and safety of interferon alpha-2b aerosol therapy for patients infected with the SARS-CoV-2 omicron variant: A randomized controlled single-blind study. Cellular Immunology. 2025. doi:10.1016/j.cellimm.2025.104992

BibTeX
@article{Jin2025,
  author = {Jin, Yinpeng and Meng, Xianming and Qian, Zhiping and Zhao, Jun and Lv, Ying and Ling, Yun and Fan, Xiaohong},
  title = {Efficacy and safety of interferon alpha-2b aerosol therapy for patients infected with the SARS-CoV-2 omicron variant: A randomized controlled single-blind study},
  journal = {Cellular Immunology},
  year = {2025},
  doi = {10.1016/j.cellimm.2025.104992}
}
Kostenlos starten →